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SUMMARY
Autocrine VEGF signaling is critical for sustaining
prostate and other cancer stem cells (CSCs), and it
is a potential therapeutic target, but we observed
that CSCs isolated from prostate tumors are resis-
tant to anti-VEGF (bevacizumab) and anti-VEGFR
(sunitinib) therapy. Intriguingly, resistance is medi-
ated by VEGF/neuropilin signaling, which is not in-
hibited by bevacizumab and sunitinib, and it involves
the induction of P-Rex1, a Rac GEF, and consequent
Rac1-mediated ERK activation. This induction of
P-Rex1 is dependent on Myc. CSCs isolated from
the PTENpc/ transgenic model of prostate cancer
exhibit Rac1-dependent resistance to bevacizumab.
Rac1 inhibition or P-Rex1 downregulation increases
the sensitivity of prostate tumors to bevacizumab.
These data reveal that prostate tumors harbor cells
with stem cell properties that are resistant to inhibi-
tors of VEGF/VEGFR signaling. Combining the use
of available VEGF/VEGFR-targeted therapies with
P-Rex1 or Rac1 inhibition should improve the effi-
cacy of these therapies significantly.
INTRODUCTION
We are interested in the contribution of vascular endothelial
growth factor (VEGF) and its receptors to prostate cancer and
the potential for VEGF-targeted therapies in the treatment of
this common cancer. Expression of VEGF is elevated in aggres-
sive prostate cancer (Tomic et al., 2012), and a recentmeta-anal-
ysis identified high VEGF expression as a prognostic factor for
poor overall survival in men with prostate cancer (Wang et al.,
2012). These and other data indicate that VEGF and VEGF re-
ceptors are feasible therapeutic targets. In fact, bevacizumab,
a humanized VEGF antibody that blocks VEGF interactions
with its tyrosine kinase receptors (VEGFRs) (Merino et al.,
2011), and sunitinib, an inhibitor of VEGFRs and other receptors
(Michaelson et al., 2014), have been used in clinical trials of pros-
tate cancer patients (Merino et al., 2011). The prevailing assump-
tion in these studies has been that these drugs target tumor
angiogenesis (Merino et al., 2011; Goel and Mercurio, 2013).
These trials did not yield a significant survival advantage, which
has discouraged the use of these inhibitors for this disease.
For example, the results from bevacizumab monotherapy were
very disappointing, with no response noted based on RECIST
(Response Evaluation Criteria in Solid Tumors) criteria, although
27% of patients exhibited a decline in prostate-specific antigen
(Reese et al., 2001). A recent study of 873 patients with aggres-
sive prostate cancer found that the addition of sunitinib to pred-
nisone did not improve overall survival compared with placebo
(Michaelson et al., 2014).
The reasons for the poor response to VEGF-targeted therapy
in prostate cancer are not well understood but need to be
considered in the context of the complexity of VEGF signaling
in cancer. In addition to its contribution to endothelial biology
and angiogenesis, VEGF signaling in tumor cells has emerged
as an important factor in tumor initiation and progression (Goel
and Mercurio, 2013; Chatterjee et al., 2013). More specifically,
compelling evidence now exists that autocrine VEGF signaling
is necessary for the function of cancer stem cells (CSCs) in pros-
tate and other cancers (Goel and Mercurio, 2013; Goel et al.,
2012). Given that CSCs have been implicated in resistance to
therapy, tumor recurrence, and metastasis (Craft et al., 1999;
Chen et al., 2013), this role for VEGF signaling is significant
and it appears to be independent of its function as a mediator
of tumor angiogenesis. The hypothesis can be formulated from
this information that the poor response of prostate tumors,
especially aggressive tumors, to anti-VEGF (bevacizumab) and
anti-VEGR therapy is that these therapies do not target CSCs
effectively despite the fact that they are dependent on VEGF
signaling. In this study, we pursued this hypothesis and sought
to investigate the mechanisms involved.
RESULTS
Cells with Stem-like Properties Are Resistant to Anti-
VEGF/VEGFR Therapies
To assess the sensitivity of prostate CSCs to anti-VEGF therapy,
we isolatedaCD44+CD24population from two freshlyharvested
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Figure 1. Characterization of Prostate Cancer Cells Resistant to VEGF-Targeted Therapy
(A and B) Cells from two human prostate tumorswere sorted using CD44 andCD24 antibodies (A). The four subpopulations isolated based on expression of CD44
and CD24 were analyzed for their sensitivity to bevacizumab (B) and ability to form prostatospheres (A).
(C) Cells from two human freshly harvested prostate tumors were sorted using ITGA6 and ITGB4 antibodies. The four subpopulations isolated based on
expression of ITGA6 and ITGB4 were analyzed for their ability to form prostatospheres and sensitivity to bevacizumab. For (B) and (C), the percentage of live cells
in three different areas was determined and mean is plotted as cell survival.
(D and E) PC3 and C4-2 sensitive and resistant cells (1,000 cells per 60-mm plate) were cultured in the presence of bevacizumab (1 mg/ml), sunitinib (20 mM), or
their respective controls for 10 days, colonies were stained with crystal violet, and colonies with more than 50 cells were counted.
(legend continued on next page)
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human prostate tumors. This population is enriched for progeni-
tor/stem cells (Hurt et al., 2008). Indeed, the CD44+CD24 (P1)
sub-population isolated from these tumors formed significantly
moreprostatospheres than theother sub-populations (Figure 1A),
and it is the only subpopulation that exhibited resistance to beva-
cizumab treatment (Figure 1B). We also sorted these prostate tu-
mors based on expression of CD49f (a6 integrin), another stem
cell marker (Colombel et al., 2012), and observed that the high-
CD49f population formed significantly more prostatospheres
and exhibited resistance to bevacizumab treatment compared
to the low-CD49f population (Figure 1C).
To understand the mechanism behind the resistance of CSCs
to bevacizumab, we exposed prostate cancer cell lines (PC3 and
C4-2) to increasing concentrations of bevacizumab until this
inhibitor no longer affected their survival (6months). To circum-
vent VEGF-independent or transactivation of VEGFRs, we sub-
sequently exposed these cells to increasing concentrations of
sunitinib, an inhibitor of VEGRs and other VEGFRs (Michaelson
et al., 2014), along with bevacizumab. However, sunitinib did
not have a significant effect on bevacizumab-resistant cells
(data not shown). The resistant cell lines generated are referred
to as PC3-R and C4-2R. As controls, we also exposed these
cell lines to control immunoglobulin G and DMSO and refer to
these as sensitive cell lines (PC3-S and C4-2S) (Figures 1D
and 1E).
Neither bevacizumab nor sunitinib inhibited the ability of the
resistant cell lines to form colonies or survive, in contrast to the
sensitive cell lines (Figures 1D, 1E, and S1A–S1D). Interestingly,
PC3-R and C4-2R cells are also resistant to pazopanib, another
VEGFR inhibitor (Figures 1F, S1E, and S1F), confirming the
pathway specificity of the observed resistance. The resistant
cell lines we generated are enriched for stem cell properties
based on the fact that they were able to form prostatospheres
and initiate tumors in NSG mice to a significantly greater extent
than the sensitive cells (Figures 1G and 1H).
Neuropilin-Mediated Rac1 Activation Promotes
Resistance to VEGF-Targeted Therapy
We compared the expression of key stem cell genes between
the sensitive and resistant cell lines to substantiate our hypothe-
sis that resistant cells exhibit stem cell properties. Indeed, the
resistant cell lines are enriched in the expression of genes asso-
ciatedwith CSCs (Nanog, Sox2, BMI1, and ALDH1) compared to
the sensitive cell lines (Figure 2A). Interestingly, VEGF expression
is markedly elevated in the resistant cell lines despite the fact
that these cells were selected based on their resistance to bev-
acizumab. In contrast, no significant difference was observed in
VEGFR2 expression between sensitive and resistant cells, and
these cells lack expression of VEGFR1 (Figure 2A). Downregula-
tion of VEGF expression in resistant cells reduced their ability to
form colonies, suggesting that VEGF signaling contributes to
bevacizumab and sunitinib resistance in a VEGFR2-independent
manner (Figures S2A and S2B). The nature of this signaling was
indicated by the observation that neuropilin (NRP) expression,
especially NRP2, is dramatically elevated in resistant cell lines
(Figures 2A and S2C). These expression data raised the possi-
bility that VEGF/NRP signaling is responsible for resistance to
bevacizumab and sunitinib, especially given the fact that bevaci-
zumab blocks the interaction of VEGFwith VEGFRs (VEGFR1–3),
but not with NRPs (Geretti et al., 2010). The observation that
IGF-1R expression is reduced dramatically in resistant cells (Fig-
ure 2A) is consistent with our previous finding that VEGF/NRP2
signaling represses IGF-1R transcription (Goel and Mercurio,
2013; Goel et al., 2012).
The contribution of NRPs to resistance was investigated using
c-furSEMA, an inhibitory peptide, which blocks interactions of
VEGF with NRPs (Parker et al., 2010). This peptide inhibited for-
mation of prostatospheres in resistant cell lines and showed no
effect in sensitive cells (Figure 2B). Importantly, treatment with
c-furSEMA or an inhibitory NRP2 antibody decreased colony
formation, highlighting a critical role for NRPs in the survival of
resistant cells (Figure S2D). We also observed that inhibition of
VEGF-NRP binding using c-furSEMA increased the sensitivity
of resistant cells to bevacizumab, substantiating the critical
function of NRPs in resistance to this VEGF inhibitor (Figure 2C).
Furthermore, downregulation of either NRP2 or NRP1 signifi-
cantly reduced colony formation and increased sensitivity to
bevacizumab (Figure S2E). We focused on NRP2 for subsequent
experiments based on our previous work (Goel and Mercurio,
2013; Goel et al., 2012) and the observation that NRP2
downregulation had amore potent inhibitory effect on colony for-
mation than NRP1 (Figure S2E). Ectopic expression of NRP2 in
sensitive cells induces resistance to bevacizumab in the pres-
ence of VEGF, directly implicating NRP2 in resistance to bevaci-
zumab (Figure S2F).
Based on our finding that VEGF/NRP signaling promotes
resistance to VEGF/VEGFR-targeted therapy, we investigated
the details of this signaling mechanism. Initially, we compared
activation of AKT and extracellular signal-regulated kinase
(ERK) in sensitive and resistant cell lines, in the absence or pres-
ence of exogenous VEGF. Sensitive cells exhibited increased
ERK activation in response to VEGF, which was inhibited by bev-
acizumab (Figure 2D). In contrast, resistant cells displayed rela-
tively high ERK activation even in the absence of exogenous
VEGF (Figure 2E), presumably the consequence of autocrine
VEGF secretion in these cells. Interestingly, bevacizumab was
unable to inhibit ERK activation in resistant cells (Figures 2F
and 2G), suggesting that VEGF can induce ERK activation in
these cells independently of VEGFR. No differences in AKT
activation were observed between sensitive and resistant cells
(Figures 2F and 2G). Since bevacizumab does not block the
interaction of VEGFwith NRP (Geretti et al., 2010), we expressed
NRP2 in sensitive cells and observed that it induced ERK activa-
tion in the presence of bevacizumab (Figures 2H and 2I). This
result implicates VEGF/NRP2 signaling in ERK activation. Inter-
estingly, RAS does not appear to be involved in this mode of
(F) PC3- and C4-2-resistant and sensitive cell lines were analyzed for colony formation in the presence or absence of 10 mM pazopanib.
(G) Resistant and sensitive PC3 and C4-2 populations were compared for their ability to form prostatospheres.
(H) Resistant and sensitive PC3 populations were implanted into NSG mice, and tumor onset was plotted.
Error bars represent mean ± SD. Beva, bevacizumab; hIgG, control immunoglobulin G. See also Figure S1.
Cell Reports 14, 2193–2208, March 8, 2016 ª2016 The Authors 2195
B0
20
40
60
80
N
o.
 o
f P
ro
st
at
os
ph
er
es
c-SEMA
c-furSEMA
PC
3-S
PC
3-R
C4
-2S
C4
-2R
*
*
A
C4-2S C4-2R PC3-S PC3-R
OCT 4 1 (0.03) 0.98 (0.02) 1 (0.07) 3.3 (0.06)
Bmi-1 1 (0.03) 2.9 (0.042) 1 (0.05) 7.6 (0.43)
GLI1 1 (0.07) 4.2 (0.28) 1 (0.09) 8.5 (0.57)
KLF4 1 (0.21) 1.39 (0.09) 1 (0.08) 0.91 (0.18)
NANOG 1 (0.042) 3.1 (0.04) 1 (0.03) 15 (1.99)
SOX2 1 (0.17) 4.8 (0.139) 1 (0.42) 5.6 (0.84)
ALDH1 1 (0.46) 2.2 (0.68) 1 (0.19) 1.9 (0.48)
ALDH2 1 (0.8) 1.6 (0.6) 1 (0.23) 1.15 (0.63)
ALDH3 1 (0.02) 0.9 (0.45) 1 (0.02) 1.4 (0.8)
Snail1 1 (0.1) 1.6 (0.5) 1 (0.09) 2.6 (0.12)
VEGF 1 (0.05) 8.7 (0.2) 1 (0.03) 6.3 (0.7)
c-Met 1 (0.13) 1.04 (0.36) 1 (0.037) 1.17 (0.42)
EGFR 1 (0.055) 0.5 (0.02) 1 (0.01) 3.6 (1.89)
IGF1R 1 (0.035) 0.12 (0.05) 1 (0.049) 0.18 (0.07)
IR 1 (0.04) 1.23 (0.52) 1 (0.15) 2.2 (1.11)
VEGFR1 0 0 0 0
VEGFR2 1.18 (0.68) 0.68 (0.12) 1 (0.23) 1.5 (0.58)
NPR1 1 (0.02) 6.3 (0.06) 1 (0.01) 6.11 (0.44)
NPR2 1 (0.042) 17.7 (1.56) 1 (0.27) 15.08 (1.99)
GROWTH FACTOR RECEPTOR
STEMNESS
pERK
ERK1/2
pERK
ERK1/2
pAKT
(Ser 473)
AKT
-
pERK
pAKT
(Ser 473)
AKT
S R
C4-2 cells, +Beva
PC
3-S
PC
3-R
pERK
pAKT
(Ser 473)
AKT
PC3 cells, +Beva
:IGF1
Active Ras
Input Ras
PC3 cells
Active-Ras
Input-Ras
C4
-2-
S
C4
-2-
R
pERK
ERK1/2
MYC
RAS
Ve
cto
r
DN
-R
as
PC3-R
pERK
ERK1/2
MYC
C4-2
Ve
cto
r
DN
-R
as
D
E
G I
K
J
ve
cto
r
CA
-M
EK
HA
PC3-S
L
0
0.25
0.75
0.5
ve
cto
r
CA
-M
EK
hIgG
Beva
DMSO
Sunit
0
25
50
75
Vector
CA-MEK
PC
3-S
PC
3-R
*
*
*
ERK1/2
ERK1/2
M
H
:VEGF+ - +
-
S R
:VEGF+ - + -
R
:VEGF+ - +
S (+NRP2)
-
R
:VEGF+ - +
S (+NRP2)
C4-2 cells, +Beva
PC3 cells, +Beva
- +
ve
cto
r
CA
-M
EK
N
o.
 o
f P
ro
st
at
os
ph
er
es
ACTIN
ACTIN
ACTIN
R
el
at
iv
e 
Ce
ll V
ia
bi
lity
 (O
D)
AKT
pAKT
(Ser 473)
-
pERK
hIgG Beva
PC
3-
S 
ce
lls
ERK1/2
:VEGF+ - +
N
-
pERK
ERK1/2
:VEGF+ - +
PC3-S PC3-R
hIgG
Beva
c-
SE
MA
c-
fur
SE
MA
0
0.2
0.4
0.6
R
el
at
iv
e 
Ce
ll V
ia
bi
lity
 (O
D)
*
C
F
Figure 2. VEGF/NRP-Mediated Activation of ERK Promotes Resistance to Therapy
(A) Expression of CSC-related genes and growth factor receptors was quantified by qPCR in resistant and sensitive populations of PC3 and C42 cells. Tables
show fold change in mRNA expression upon normalization with sensitive populations, which was set as 1.
(legend continued on next page)
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ERK activation based on the findings that no differences in the
levels of active RAS were detected between sensitive and resis-
tant cells (Figures 2J and 2K) and that expression of a dominant-
negative RAS (DN-RAS) did not alter ERK activation in resistant
cells (Figure 2L). ERK activation contributes to resistance based
on the finding that expression of constitutively active MEK in
sensitive cells increased their resistance to bevacizumab and
sunitinib-mediated inhibition of viability and prostatosphere
formation (Figures 2M and 2N).
Subsequently, we focused on Rac1 as a mediator of Ras-
independent ERK activation based on the reports that Rac1 is a
major effector of NRP/plexin signaling (Liu and Strittmatter,
2001; Riccomagno et al., 2012) and plays a central role in
vascular development in response to VEGF (Tan et al., 2008).
Also, activation of Rac1 is associated with aggressive prostate
cancer (Kobayashi et al., 2010), and Rac1/ mice exhibit
impaired ERK activation and regression of hematopoietic stem
cells (Gu et al., 2003). Indeed, we found that resistant cell lines
exhibit robust Rac1 activation compared to sensitive cells (Fig-
ure 3A). Rac1 mediates ERK activation in resistant cells based
on the use of a dominant-negative Rac construct (Figure 3B).
The activity of Rac1 in resistant cells is dependent upon NRP
signaling because c-furSEMA reduced Rac1 activity significantly
(Figure 3C). In contrast, addition of recombinant VEGF did not
increase Rac1 activity or the ability of these cells to make prosta-
tospheres (Figure 3D),most likely because resistant cells express
high levels of autocrine VEGF (Figure 2A). This possibility was
confirmed by depleting VEGF expression in these cells and
observing a marked reduction in Rac1 activity (Figure 3E).
Sensitive cells may not respond to VEGF and activate Rac1
because they lack significant NRP expression. To test this
possibility, we expressed either NRP1 or NRP2 in these cells
and observed an increase in Rac1 activity and prostatosphere
formation (Figure 3F). Also, expression of a constitutively
active Rac1 in sensitive cells increased prostatosphere forma-
tion and expression of a dominant-negative Rac1 in resistant
cells decreased their formation (Figure 3G). These results
were confirmed using a Rac1 inhibitor (EHT1864) in resistant
cells, which reduced the number of prostatospheres (Fig-
ure 3H). Although there is some indication that the ability of
EHT1864 to inhibit Rac1 may be indirect (data not shown),
we conclude from the use of dominant-negative and constitu-
tively active Rac1 constructs, as well as EHT1864, that Rac1 is
the primary mediator of VEGF/NRP-mediated prostatosphere
formation.
To validate the role of Rac1 in tumor initiation, we utilized the
PTENpc/ transgenic mouse model of prostate cancer (Mulhol-
land et al., 2009). Tumors that form in this model harbor a small
population of tumor initiating cells defined as LinSca+CD49fhigh
(referred to as LinSca+CD49fhigh [LSC] cells) (Mulholland et al.,
2009). We purified these LSC cells from 10-week-old PTENpc/
mice and observed increased expression of VEGF and NRP2 in
this population compared to non-LSC cells (Figure S2G). We
tested the hypothesis that Rac inhibition increases sensitivity
to mcr84, which recognizes both mouse and human VEGF (Sul-
livan et al., 2010), and sunitinib. This antibody (mcr84) does not
inhibit the interaction of VEGF with NRPs (Figure S2H). Consis-
tent with our hypothesis, we observed that the Rac1 inhibitor
increased the sensitivity of LSC cells to these drugs (Figure 3I).
Inhibition of Rac1 also reduced the expression of VEGF, NRP2
and other stemness-related genes (Figure 3J).
The data in Figure 3I suggest that the response to VEGF-
targeted therapy (bevacizumab or mcr84) would be improved
significantly if Rac1 expression or activation were inhibited. To
test this possibility initially, we treated control and Rac1-
depleted PC3-R xenografts with bevacizumab or vehicle. Beva-
cizumab treatment alone had no significant effect on tumor
growth, validating our in vitro finding that resistant cell lines
can tolerate bevacizumab treatment. Although Rac1 inhibition
reduced tumor volume, the combination of bevacizumab and
Rac1 depletion resulted in a significantly better decrease in
tumor volume (Figure 4A). Moreover, the residual tumors har-
vested from mice that received the combined treatment con-
tained mostly apoptotic cells, in contrast to either bevacizumab
treatment or Rac1 inhibition alone (Figure 4B). This unexpected
observation suggests that resistant cells acquire sensitivity to
bevacizumab as a result of Rac1 inhibition. Presumably, Rac1
inhibition alone reduces tumor growth but does not induce the
massive apoptosis seen with combined treatment. To pursue
this hypothesis further, PTENpc/ transgenic mice were treated
with the Rac1 inhibitor (EHT1864), mcr84, or both at the start of
puberty (6 weeks). Indeed, Rac1 inhibition reduced the number
of LSC cells significantly but the combined treatment abolished
the LSC population. We also compared the impact of mono- and
(B and C) Resistant and sensitive populations were analyzed for prostatosphere formation (B) or sensitivity to bevacizumab (1 mg/ml) (C) in the presence of either
a NRP inhibitory peptide (c-furSEMA) or control peptide (c-SEMA).
(D) PC3-S cells were serum-deprived overnight and stimulated with VEGF (50 ng/ml) for 30 min in the presence or absence of bevacizumab (5 mg/ml). The
activation of ERK was analyzed by immunoblotting using a phospho-specific antibody.
(E) PC3-sensitive or resistant cells were serum-deprived overnight and stimulated with VEGF (50 ng/ml) for 30 min. The activation of ERK was analyzed by
immunoblotting using a phospho-specific antibody.
(F and G) Sensitive and resistant PC3 and C4-2 cell lines were serum-deprived overnight and stimulated with VEGF (50 ng/ml) for 30 min in the presence of
bevacizumab (5 mg/ml). The activation of ERK and AKT was analyzed by immunoblotting using phospho-specific antibodies.
(H and I) NRP2 was expressed in sensitive populations of PC3 and C4-2 cells. These cells and resistant PC3 and C4-2 cells serum-deprived overnight and
stimulated with VEGF (50 ng/ml) for 30 min in the presence of bevacizumab (5 mg/ml). The activation of ERK and AKT was analyzed by immunoblotting.
(J) Ras activation was analyzed in sensitive and resistant PC3 and C4-2 cell using the Raf1 binding assay.
(K) PC3-S cells were stimulated with IGF-1 (100 ng/ml) for 20 min and Ras activation was analyzed.
(L) Resistant PC3 and C4-2 cells were transfected with a Myc-tagged dominant-negative (DN) Ras construct, and ERK activation was analyzed by immuno-
blotting.
(M and N) Sensitive PC3 cells were transfected with a hemagglutinin (HA)-tagged, constitutively active (CA) MEK construct, and sensitivity to bevacizumab (M)
and the effect on prostatosphere formation (N) were analyzed.
Error bars represent mean ± SD. Beva, bevacizumab; hIgG, control immunoglobulin G. See also Figure S2.
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combined therapy on PTENpc/ tumors by calculating the
weights of the isolated genitourinary (GU) tracts and prostate
lobes. Combined treatment (EHT1864 + mcr84) resulted in a
significant decrease in the weight of the isolated GU tracts and
prostate lobes compared to either EHT1864 or mcr84 alone
(Figures 4C and 4D). Pathological examination revealed that
tumors progressed to well-differentiated adenocarcinomas in
mice that received either control or single-agent treatment. Inter-
estingly, however, prostatic intraepithelial neoplasia (PIN) le-
sions were observed in the prostate glands of mice that received
combined treatment (RACi +mcr84), suggesting a delay in tumor
progression as a result of the reduced number of LSC cells
(Figure 4E). Moreover, a mass of cells in the lumen of the gland
was evident in mice that received the combined treatment.
Further analysis using the TUNEL assay demonstrated that this
mass of cells is apoptotic, indicating that combined treatment
can induce apoptotic cell death within PIN lesions (Figures 4F
and S3). We also stained these tumor groups with CD31 and
observed no significant difference in staining among the groups,
indicating that the observed impact of these treatments is
not caused by an effect of these compounds on angiogenesis
(Figure S4A).
Identification of P-Rex1 as theMediator of Resistance to
VEGF-Targeted Therapy
To understand how VEGF/NRP signaling activates Rac1 and
promotes resistance to VEGF/VEGFR-targeted therapy, we
compared the expression of potential guanine-nucleotide ex-
change factors (GEFs) known to be involved in Rac1 activity in
sensitive and resistant cells (Figure 5A). This screening revealed
elevated expression of P-Rex1 and, to as lesser extent, TIAM1 in
resistant cells (Figure 5A). The importance of P-Rex1 in Rac1
activation is indicated by our finding that expression of exoge-
nous P-Rex1 in VEGF-depleted resistant cells or in sensitive cells
restored Rac1 activation (Figures 5B and S4B). In contrast,
downregulation of TIAM1 expression in resistant cells had no
effect on Rac1 activation (Figure 5C), suggesting that endoge-
nous P-Rex1 is sufficient to maintain Rac1 activation even in
the absence of TIAM1. For this reason, we focused subsequent
experiments on P-Rex1. P-Rex1 expression is dependent upon
VEGF/NRP signaling because downregulation of VEGF signifi-
cantly reduced P-Rex1 expression in resistant cells (Figure 5D)
and expression of either NRP1 or NRP2 in sensitive cells
increased P-Rex1 expression (Figure 5E). Moreover, depletion
of P-Rex1 expression in resistant cells diminished Rac1 activity
and prostatosphere formation (Figure 5F). The importance of
P-Rex1 in promoting resistance is indicated by the finding that
downregulation of P-Rex1 in resistant cells increased their sensi-
tivity to bevacizumab and sunitinib (Figure 5G).
Our P-Rex1 experimental results were validated by analyzing
the gene expression profiles of epithelial cells micro-dissected
from benign prostates and tumor cells from Pten-null prostate
carcinomas (Garcia et al., 2014). P-Rex1 expression is signifi-
cantly elevated in cancer cells compared to benign epithelium
(p = 0.04) (Figure 5H). We also compared the expression
levels of Rac GEFs in LSC and non-LSC cells isolated from
PTENpc/ prostate tumors. Among all of the GEFs analyzed,
only P-Rex1 expression is increased significantly in LSC com-
pared to non-LSC cells (Figure 5I). P-Rex1 expression is higher
in prostate adenocarcinoma compared to non-cancerous tis-
sues (Qin et al., 2009). More specifically, we observed that
P-Rex1 expression correlates with tumor grade (Figure 5J),
similar to NRP2 expression (Goel et al., 2012). In fact, a positive
correlation between P-Rex1 and NRP2 expression was detected
in a cohort of prostate tumors (Figure 5J).
To demonstrate that VEGF-induced tumor initiation is depen-
dent upon Rac1 activation, we engineered PC3 cells to express
GFP under control of the VEGF promoter. We sorted these cells
and generated two distinct populations designated VEGFhigh
and VEGFlow (Figure 6A). VEGFhigh cells form more colonies in
soft agar and initiate tumorsmore rapidly than VEGFlow cells (Fig-
ures 6B and 6C). Similar to the resistant cell lines described
above, VEGFhigh cells express high levels of genes associated
with CSCs, NRPs, and P-Rex1 (Figure 6D). Also, the VEGFhigh
cells are more resistant to bevacizumab and sunitinib compared
to the VEGFlow cells (Figure 6E). VEGF induces ERK activation,
which is inhibited by bevacizumab in VEGFlow cells (Figure 6F).
In contrast, VEGFhigh cells exhibit high basal ERK activation
and this activation is resistant to bevacizumab (Figure 6F).
VEGFhigh cells also exhibited increased Rac1 activity compared
Figure 3. Rac1 Mediates Stem Cell Properties and Resistance to VEGF-Targeted Therapy
(A) Rac1 activation was compared in resistant and sensitive PC3 and C4-2 cells.
(B) Resistant PC3 cells were transfected with a glutathione S-transferase (GST)-tagged dominant-negative (DN) Rac1 construct and stimulated with VEGF, and
activation of ERK was analyzed by immunoblotting. GST expression indicates the level of DN-Rac expression.
(C) Rac1 activation was measured in resistant PC3 cells in response to VEGF treatment in the presence of either a NRP inhibitory peptide (c-furSEMA) or control
peptide (c-SEMA).
(D) Resistant and sensitive PC3 cells were stimulated with VEGF and the effect on Rac1 activation and prostatosphere formation was measured.
(E) VEGF expression was diminished in resistant PC3 and C4-2 cells using two different shRNAs and the effect on Rac1 activation was determined.
(F) Either NRP1 or NRP2 was expressed in sensitive PC3 cells. These cells were stimulated with VEGF (50 ng/ml) for 30 min and the effect on Rac1 activation and
prostatosphere formation was measured.
(G) Resistant and sensitive PC3 cells were transfected with a GST-tagged, dominant-negative Rac construct (DN-Rac) or a constitutively active Rac construct
(CA-Rac), and their effect on prostatosphere formation was measured.
(H) PC3-R cells were stimulated with VEGF in the presence or absence of a Rac1 inhibitor (EHT1864; 20 mM) and the effect on prostatosphere formation was
measured.
(I) Freshly sorted LSC cells from PTENpc/ mice were used to measure the effect of EHT1864, mcr84, or sunitinib on cell proliferation and prostatosphere
formation.
(J) Freshly sorted LSC cells from PTENpc/ mice were treated with EHT1864 (20 mM), and expression of genes associated with stem cells and VEGF signaling
was quantified by qPCR.
Error bars represent mean ± SD.
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to the VEGFlow cells (Figure 6G). Also, downregulation of NRP2 in
VEGFhigh cells reduced Rac1 activation (Figure 6H). Importantly,
inhibition of Rac1 in VEGFhigh cells reduced their ability to form
prostatospheres in vitro and tumors in vivo (Figures 6I and 6J).
Also, P-Rex1 downregulation reduced tumor onset in vivo (Fig-
ure 6K), confirming the crucial role of P-Rex1 in VEGF/NRP/
Rac1 signaling. Taken together, these data substantiate the abil-
ity of VEGF/NRP2/P-Rex1 signaling to activate Rac1 and the
importance of this pathway in tumor formation.
To identify the mechanism of P-Rex1 regulation, we focused
on its transcriptional regulation, because we observed
increased activity of a luciferase reporter construct containing
the P-Rex1 promoter in resistant cells compared to sensitive
cells (Figure 7A). We used the UCSC genome browser to search
for putative transcription factor binding sites on the P-Rex1
promoter and identified Myc as a possible candidate. A role
for Myc is supported by the increased expression of Myc in
resistant compared to sensitive cell lines, as well as enrichment
of Myc-positive cells in PTENpc/ tumors upon treatment with
mcr84 (Figures 7B and 7C). Moreover, Myc downregulation
reduced Rac1 activation and P-Rex1 expression in resistant
cells (Figures 7D, 7E, S5A, and S5B). More definitively, we
detected direct binding of Myc on the P-Rex1 promoter by
ChIP (Figure 7F), and mutation of a putative myc-binding site
(CACTTG, 246) significantly reduced the activity of a luciferase
promoter construct (Figure S5C). We also found a significant
correlation in P-Rex1 and Myc expression in human prostate
cancer specimens by immunohistochemistry (Figures 7G and
S5D). These results infer that VEGF/NRP regulation of P-Rex1
is Myc dependent. Indeed, we observed that VEGF was unable
to induce P-Rex1 expression in the presence of Myc small
hairpin RNA (shRNA) in PC3-S cells engineered to express
NRP2 (Figure 7E). Expression of Myc is VEGF dependent based
on the findings that downregulation of VEGF reduced Myc
expression and addition of VEGF increased Myc expression
(Figures 7B and 7E).
Myc is a regulator of prostate cancer and prostate-specific
expression of a Myc transgene drives carcinogenesis in a
stepwise fashion from PIN to invasive cancer (Ellwood-Yen
et al., 2003). Myc-Cap cells were derived from this transgenic
mouse model. Inhibition of Rac1 in Myc-CaP cells reduced
their ability to form colonies in soft agar (Figure 7H). Moreover,
downregulation of Rac1 or P-Rex-1 expression significantly
increased tumor-free survival in vivo, establishing the impor-
tant role of Rac1/P-Rex1 in Myc-induced tumorigenesis (Fig-
ures 7I–7K).
DISCUSSION
This study was predicated on the results from clinical trials
concluding that bevacizumab and VEGF receptor tyrosine ki-
nase inhibitors are not effective therapies for prostate cancer
(Merino et al., 2011). It is widely assumed that these drugs target
tumor angiogenesis (Merino et al., 2011) and, consequently, the
poor response observed in these clinical trials could be consid-
ered in the context of angiogenesis and the role of angiogenesis
in prostate cancer. In contrast to this prevailing idea, we focused
on the hypothesis that VEGF signaling in tumor cells, especially
cells with stem-like properties, is critical for tumor propagation
and progression and that this signaling, mediated primarily by
NRPs, is a prime target for therapy (Goel and Mercurio, 2013).
Indeed, the results we report demonstrate that prostate can-
cer cells selected for their resistance to bevacizumab and suni-
tinib are enriched for stem cell properties and NRP signaling.
Most importantly, we demonstrate that NRP signaling induces
expression of P-Rex1, a Rac1 GEF, and that Rac1-mediated
ERK activation is responsible for resistance to bevacizumab
and sunitinib. These findings reveal a role for VEGF/NRP-medi-
ated regulation of P-Rex1 in the biology of CSCs and resistance
to therapy.
An intriguing aspect of our study is the ‘‘VEGF paradox.’’ Spe-
cifically, we observed that resistance to VEGF-targeted therapy
(bevacizumab and sunitinib) is mediated by an enhancement of
VEGF/NRP signaling. In fact, prostate cancer cells treated with
bevacizumab and sunitinib exhibit a marked increase in VEGF
expression despite the fact that bevacizumab targets the inter-
action of VEGF with VEGFRs (Ferrara, 2005). Our interpretation
of these data is that neither bevacizumab nor sunitinib is effective
at targeting prostate cancer cells with stem cell properties and
that the CSC population, which is characterized by autocrine
VEGF/NRP signaling, is enriched by treatment with these drugs
because they target primarily non-CSCs. This hypothesis is sup-
ported by several studies that have highlighted the importance of
VEGF/NRP signaling in CSCs and discounted the contribution of
VEGFRs (Goel andMercurio, 2013). In light of our data that resis-
tant cells show lack of VEGF2 surface expression, we propose
that NRP2-mediated VEGF signaling is independent of its role
as a co-receptor for VEGFRs. This hypothesis is consistent
with previous reports that VEGF/NRP signaling can occur inde-
pendently of VEGFRs (Goel and Mercurio, 2013; Cao et al.,
2013). Moreover, our previous observation that NRP2 associates
with the a6b1 integrin and regulates CSC properties by acti-
vating focal adhesion kinase (FAK) (Goel et al., 2012, 2013)
Figure 4. Rac1 Inhibition Improves Sensitivity to VEGF-Targeted Therapy
(A) PC3-R cells were transfected with Rac1 shRNAs, and these cells were implanted in NSGmice. Once tumors reached100 mm3 in volume, mice were treated
with either control immunoglobulin G (Cont) or bevacizumab (Bev; 10 mg/kg, intraperitoneally [i.p.], twice weekly). Tumor volume was measured every third day.
(B) Control and treated PC3-R xenograft tumors were harvested, and apoptosis was analyzed using TUNEL staining. Scale bar, 10 mm.
(C and D) Six-week old PTENpc/ mice were injected i.p. with either mcr84 (10 mg/kg) or EHT1864 (10 mg/kg) twice weekly for 3 weeks. The GU tract was
harvested, and total weight was measured. The prostate glands were separated and combined weight of all the lobes was measured. The prostate glands were
digested, and LSC cells (LinSca+CD49fhigh) were isolated by fluorescence-activated cell sorting. The number of LSC cells is significantly reduced inmice treated
with RACi or RACi+mcr84.
(E) H&E staining of prostate tumors from PTENpc/ mice described in (C). The percentage of prostate glands showing either PIN or well-differentiated
adenocarcinoma (AdCa) was quantified as shown. Scale bar, 100 mm.
(F) Tumor sections of prostate tumors from PTENpc/ mice described in (C) were stained using the TUNEL reagent to detect apoptosis. Scale bar, 100 mm.
Error bars represent mean ± SD. Bev, bevacizumab; hIgG, control immunoglobulin G. See also Figures S3 and S4.
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Figure 5. P-Rex1, a GEF, Promotes Rac1 Activation and Resistance to VEGF-Targeted Therapy
(A) The expression of Rac1 GEFs was compared in sensitive and resistant PC3 and C4-2 cell lines using qPCR. Table shows fold change in mRNA expression
upon normalization with sensitive populations, which was set as 1.
(B) P-Rex1 was expressed in resistant PC3 cells in which VEGF expression had been diminished using shRNA and the effect on Rac activation was determined
(left). P-Rex1 was expressed in resistant and sensitive PC3 cells and the effect on Rac activation was determined (middle). Right panels show the expression of
HA-tagged P-Rex1 in PC3-R cells.
(C) Resistant PC3 cells were transfected with either P-Rex1 shRNA or TIAM1 siRNA, and the effect on Rac activation was determined.
(D)Proteinextracts fromresistantPC3cells inwhichVEGFexpressionhadbeendiminishedusingshRNAwere immunoblottedwithP-Rex1,VEGF,oractinantibodies.
(E) Either NRP1 or NRP2 was expressed in sensitive PC3 cells, and the effect on P-Rex1 expression was assessed by immunoblotting.
(F) Resistant PC3 cells were transfected with P-Rex1 shRNA, and the effect on prostatosphere formation and Rac1 activation was analyzed.
(G) Resistant PC3 cells expressing P-Rex1 shRNA were treated with bevacizumab (Bev; 1 mg/ml) or sunitinib (Sunit; 20 mM), and their proliferation was assayed.
Beva, bevacizumab; hIgG, control immunoglobulin G.
(H) Expression of P-Rex1 was analyzed in a published dataset (GEO: GSE56469).
(I). Freshly harvested LSC cells from 9-week-old PTENpc/ mice were analyzed for expression of GEFs using qPCR.
(J) Expression of NRP2 and P-Rex1 mRNA was quantified by qPCR in microdissected sections from benign glands, as well as grade 3 and grade 5 prostate
cancer specimens. A significant correlation (p value is 1 3 106) in the expression of P-Rex1 and NRP2 was observed (r = 0.7).
Error bars represent mean ± SD.
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Figure 6. Rac1 Is Required for VEGF-Mediated Tumor Initiation
(A) PC3 cells were transfected with a GFP-expressing plasmid under control by the VEGF promoter and these cells were sorted based on their expression of GFP.
The top panels show fluorescence-activated cell sorting (FACS) profile before GFP sorting, and the bottom panels show FACS profile after sorting.
(B) The ability of VEGFhigh and VEGFlow cells to form colonies in soft agar was determined.
(C) VEGFhigh and VEGFlow cells were implanted in NSG mice and tumor formation was detected by palpation.
(D) Expression of genes associated with stem cells and VEGF signaling was quantified by qPCR.
(E) VEGFhigh and VEGFlow cells were incubated with bevacizumab (Bev; 1 mg/ml) or sunitinib (Sunit; 20 mM) for 72 hr, and their proliferation was assayed. Beva,
bevacizumab; hIgG, control immunoglobulin G.
(legend continued on next page)
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provides a potential mechanism for VEGF signaling that is inde-
pendent of VEGFRs because FAK is known to mediate ERK acti-
vation (Zhao and Guan, 2009) and is important for CSCs (Luo
et al., 2009).
Our data reveal an unexpected role for P-Rex1 and Rac1 acti-
vation in the genesis of prostate CSCs and resistance to bevaci-
zumab and sunitinib. P-Rex1 is quite interesting in this regard
because its expression is low in normal prostate and elevated
in metastatic disease (Qin et al., 2009). There is also evidence
that P-Rex1 can promote metastasis in a xenograft model of
prostate cancer (Qin et al., 2009). Although many studies have
implicated Rac1 in migration, invasion, initiation, and growth of
tumor cells, including prostate cancer (Bid et al., 2013; Baker
et al., 2014), our results show that P-Rex1-mediated Rac1 acti-
vation is critical for the formation and function of prostate
CSCs. This conclusion is demonstrated most rigorously by our
observation that treatment of mice harboring PTENpc/ tumors
with a Rac1 inhibitor significantly reduced the number of LSC
cells, which have been characterized as CSCs in this transgenic
model (Mulholland et al., 2009). Also, treatment of these mice
with the Rac1 inhibitor reduced the frequency of tumor forma-
tion, consistent with a role for Rac1 in the function of CSCs.
We also provide evidence that Rac1-mediated activation of
ERK is responsible for resistance to bevacizumab and sunitinib.
We provide mechanistic insight into the regulation of P-Rex1
expression by identifyingMyc as a regulator of P-Rex1 transcrip-
tion in prostate CSCs. This finding is relevant because Myc is
significantly elevated in prostate CSCs compared to non-CSCs
(Civenni et al., 2013). Also, gene set enrichment analysis of two
independent datasets revealed that Myc expression is associ-
ated with tumor cells enriched with an embryonic stem cell-like
gene signature (Civenni et al., 2013). Our data also indicate
that VEGF/NRP signaling contributes to the regulation of Myc
expression and Myc-induction of P-Rex1. This conclusion is
supported by the report that VEGF/VEGFR2 signaling induces
Myc expression in breast cancer cells by a mechanism that in-
volves Stat 3 (Zhao et al., 2015). Based on our data, however,
VEGF induction of Myc appears to be independent of VEGFRs.
In this direction, we reported that VEGF/NRP signaling activates
FAK in CSCs. (Goel et al., 2012, 2013). This observation is inter-
esting based on the report that FAK regulates Myc transcription
in epidermal stem cells (Ridgway et al., 2012). It is also worth
noting that epigenetic repression of P-Rex1 in non-aggressive
prostate cancer cell lines has been observed (Wong et al.,
2011). However, our initial experiments suggested that epige-
netic regulation does not account for the marked increase in
P-Rex1 mRNA expression in PC3-R cells compared to PC3-S
(Figure S6A).
An important question that arises from our data is how
P-Rex1-mediated Rac1 activation impacts the function of pros-
tate CSCs and promotes resistance to therapy. We posit that
P-Rex1/Rac1-mediated ERK activation sustains the expression
of VEGF and NRP2 and the ability of VEGF/NRP2 signaling to
enhance the expression of BMI-1 and other stem cell factors.
In essence, we suggest that p-Rex1/Rac1-mediated ERK acti-
vation contributes to a positive feedback loop involving VEGF/
NRP2 signaling that sustains stem cell properties in prostate
cancer. In addition, our previous work demonstrated that
VEGF/NRP2 signaling contributes to ERK-mediated induction
of Gli1 and BMI-1 expression and that this pathway can feed-
back to sustain NRP2 expression (Goel et al., 2013). These
findings should be discussed in the context of a recent report
concluding that autocrine semaphorin 3C promotes the survival
of glioma stem cells by activating Rac1/nuclear factor kB
signaling (Man et al., 2014). In contrast to our results, however,
they observed that semaphorin-3C-mediated Rac1 activation
does not impact ERK activation or the expression of stem
cell factors. We also analyzed the expression of semaphorin
3C and targets of nuclear factor kB signaling and found no dif-
ference between sensitive and resistant populations (Figures
S6B–S6D). Clearly, the available data indicate that Rac1 can
affect the function of CSCs by distinct mechanisms that may
relate to the biology of specific cancers. It is also worth noting
that both semaphorin 3C and VEGF are ligands for NRP2, and
an important aspect of our work is that we implicate VEGF-
mediated activation of P-Rex1/Rac1 in resistance to bevacizu-
mab, which has significant therapeutic implications. Interest-
ingly, in this context, our analysis of gene profiling of metastatic
colon cancer patients treated with bevacizumab revealed that
high P-Rex1 or Myc expression is a significant predictor of
poor progression-free survival (Figure S6E) (Pentheroudakis
et al., 2014). Also, the analysis of gene expression in human
glioblastoma xenografts treated with bevacizumab indicated
increased expression of P-Rex1 and NRP2 (Figure S6F).
Unfortunately, it is not possible to perform a similar analysis
of prostate cancer patients treated with either bevacizumab
or sunitinib (Michaelson et al., 2014; Kelly et al., 2012) because
tumor specimens were not collected as an endpoint in these
clinical trials (W.K. Kelly and M.D. Michaelson, personal
communication).
Our data raise the exciting possibility that bevacizumab or
VEGFR-targeted therapy in prostate cancer could be efficacious
if it were combined with targeted inhibition of P-Rex1/Rac1. This
possibility is supported by the data presented in Figures 4A and
6K. It is also timely and significant because there are few thera-
peutic options available for men with aggressive prostate can-
cer, which is enriched with tumor cells with a stem-like pheno-
type (Chen et al., 2013). Potent Rac1 inhibitors are available
(Montalvo-Ortiz et al., 2012), but some concern is noted with
their potential side effects as indicated by the reduced weight
(F) VEGFhigh and VEGFlow cells were serum-deprived overnight and stimulated with VEGF (50 ng/ml) for 30 min in the presence or absence of bevacizumab
(5 mg/ml). The activation of ERK was analyzed by immunoblotting using a phospho-specific antibody.
(G) Rac1 activation was compared in VEGFhigh and VEGFlow cells.
(H) NRP2 expression in VEGFhigh cells was downregulated using shRNA, and Rac1 activation was assayed.
(I) Prostatosphere formation by VEGFhigh cells in the presence or absence of EHT1864 was quantified.
(J and K) VEGFhigh cells were transfected with shRNAs targeting either Rac1 (J) or P-Rex1 (K), and these cells were implanted in NSGmice. Tumor formation was
detected by palpation.
Error bars represent mean ± SD.
2204 Cell Reports 14, 2193–2208, March 8, 2016 ª2016 The Authors
15
2
3
4
0
PC
3-S
PC
3-R
C4
-2S
C4
-2R
*
*
Fo
ld
 C
ha
ng
e 
A
MYC
ACTIN
0
30
60
90
RAC1
ACTIN
GF
P-
sh
RA
C1
-sh
1
RA
C1
-sh
2S
of
t a
ga
r c
ol
on
ie
s
E
6
2
4
0
Fo
ld
 C
ha
ng
e
P1 P2 P3 P4 P5
P1 -1954/-1814
P2 -1641/-1553
P3 -1174/-1058
P4 -792/-720
P5 -548/-399
CB
F
PC
3-S
PC
3-R
C4
-2S
C4
-2R
IgG
MYC
*
*
Co
ntr
ol
EH
T1
86
4
*
28 35 42 49 56 63 70 77
0
20
40
60
80
100
Days
Tu
m
or
 fr
ee
 s
u r
vi
va
l
GFP1-sh
RAC1-sh1
RAC1-sh2
p=0.0066
MYC P-Rex1  Observed      Expected
Agreement   Agreement     Kappa       Prob>Z
-----------------------------------------------------------------
  77.91%      59.84%         0.4498        0.0000
The Kappa estimate (0.45) is highly significant (P<0.0001)
D
P-Rex1 promoter 
Luciferase
G
Number of samples MYC P-Rex1
54 Positive Positive
17 Positive Negative
2 Negative Positive
13 Negative Negative
P-Rex1
MYC
ACTIN
H
PC3-R
GF
P-
sh
MY
C-
sh
ACTIN
- :VEGF+ - +
P-Rex1
ACTIN
PC3-S (+NRP2)
GF
P-
sh
MY
C-
sh
I
M
yc
-C
aP
Myc
Myc
VEGF
Actin
GF
P-s
h
VE
GF
-sh
1
VE
GF
-sh
2
PC3-R
J
C
on
tro
l
m
cr
84
MYC DAPI
Myc
GF
P-
sh
MY
C-
sh
GF
P-
sh
MY
C-
sh
Rac-active
Rac-input
PC3-R C4-2R
ACTIN
Tu
m
or
 1
Tu
m
or
 2
28 35 42 49 56
0
20
40
60
80
100
GFP1-sh
PREX1-sh1
PREX1-sh2
Days
Tu
m
or
 fr
ee
 s
ur
v i
va
l
p=0.04
K
GF
P-
sh
PR
EX
1-s
h-1
PR
EX
1-s
h-2
0
0.4
0.8
1.2
Fo
ld
 c
ha
ng
e 
(q
P
C
R
) P-Rex1
Figure 7. Myc Regulates PREX1 Transcription in Resistant Cells
(A) A luciferase reporter construct containing the P-Rex1 promoter was expressed in sensitive and resistant PC3 and C4-2 cells, and luciferase activity was
measured and normalized to Renilla.
(legend continued on next page)
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of the GU tract in response to EHT1864 (Figure 4D). Targeting
P-Rex1, however, may be more feasible based on our data.
Nonetheless, our data demonstrate that P-Rex1/Rac1 inhibition
reduces stem cell properties and renders tumor cells more
sensitive to VEGF-targeted therapies.
EXPERIMENTAL PROCEDURES
Animal Studies
All mouse experiments were performed following a protocol approved by the
Institutional Animal Care and Use Committee of the University of Massachu-
setts Medical School.
Cell Lines
PC3 (ATCC), C4-2 (UroCor), and MyC-CaP (provided by Dr. Charles L.
Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY) were
used. shRNA clones from the RNAi Consortium library were obtained from
RNAi core, University of Massachusetts Medical School.
Cell-Based Assays
The chemosensitivity of prostate cancer cells was determined using a
standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
cytotoxicity assay (Mosmann, 1983). The assay was performed 72 hr after
treatment. Fluorescence-activated cell sorting was used to isolate cells based
on their surface expression of CD44, CD24, and a6 and b4 integrins. The
detailed procedure for isolating LSC cells from PTENpc/ mice using lineage
markers (CD31, CD45, and Ter119), Sca-1, and CD49f is described previously
(Mulholland et al., 2009; Lawson et al., 2007).
Isolation of Human Prostate Tumor Cells and Laser Capture
Microscopy
Human prostate tumor tissue was obtained from UMASS Cancer Center Tis-
sue Bank in compliance with the institutional review board of the University
of Massachusetts Medical School. The discarded but freshly resected,
prostate tumors were digested with collagenase at 37C, and epithelial cells
were isolated using an EpCaM antibody. Frozen sections weremicrodissected
by laser capture microscopy (Arcturus PixCell 2) as described elsewhere (Goel
et al., 2012) to obtain pure populations of tumor cells of defined Gleason
grades. RNA was isolated from these microdissected samples using the
RNeasy kit (QIAGEN), and cDNA was prepared using Superscript II reverse
transcriptase (Invitrogen). Quantitative real-time PCR was done using the
TaqMan assay kit (Applied Biosystems).
Promoter Activity and ChIP Assays
Prostate cancer cells were transfected with the P-Rex1 promoter luciferase
construct (2021/+3) and Renilla luciferase construct to normalize for trans-
fection efficiency. Relative light units were calculated upon normalization
with Renilla luciferase activity. ChIP assays were performed according to
our published protocol (Goel et al., 2012). All ChIP experiments were repeated
at least two times. The sequence of primers used to amplify the P-Rex1 pro-
moter is provided in Figure S6G.
Statistics
Unless otherwise cited, all values are presented as the mean ± SD. For the
Student’s t test, comparisons between two groups were performed using
two-tailed, assuming equal variance among groups. A p value less than 0.05
was considered significant. The correlation of Myc and P-Rex1 expression
in human prostate cancer specimens was done using kappa statistics. The
kappa estimate was tested against a null hypothesis of kappa = 0.0. For tu-
mor-free survival xenograft experiments, the comparison between two curves
was done using the log-rank (Mantel-Cox) test. All experiments were repeated
at least twice with the exception of experiments involving the culture of primary
tumor cells, and data from one representative experiment are shown.
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Supplemental Information includes seven figures and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2016.02.016.
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(B) Myc expression was compared between sensitive and resistant PC3 and C4-2 cells by immunoblotting (left). VEGF expression was downregulated in PC3-R
cells using shRNAs, and the effect on Myc expression activation was determined by immunoblotting (right).
(C) Six-week-old PTENpc/mice were injected (i.p.) with mcr84 (10 mg/kg) twice weekly for 3 weeks. The prostate glands were harvested and immunostained
using a myc antibody.
(D) Myc expression was downregulated in resistant PC3 and C4-2 cells using shRNA, and the effect on Rac1 activation was determined.
(E) Myc expression was downregulated in PC3-R cells using shRNA, and the effect on P-Rex1 expression was determined (left). Right: NRP2-expressing PC3-S
cells were transfected with either GFP-sh or Myc-sh and stimulated with VEGF (50 ng/ml) for 24 hr, and the effect on P-Rex1 andMyc expression wasmeasured.
(F) ChIP was performed using a Myc antibody and regions of the PREX1 promoter that bound Myc were identified and quantified by qPCR.
(G) The expression of Myc and P-Rex1 was analyzed in human prostate cancer specimens by immunohistochemistry. A significant correlation of their expression
was detected. The kappa estimate (0.45) is highly significant (p < 0.0001), and it was tested against a null hypothesis of kappa = 0.0. Scale bar, 100 mm.
(H) The ability of Myc-CaP cells to form colonies in soft agar in the presence or absence of EHT1864 was determined.
(I and J)Myc-CaP cells were transfected with two different Rac1 shRNAs, and the effect on Rac1 expressionwas detected by immunoblotting (I). These cells were
implanted into NSG mice, and tumor onset was determined by palpation (J).
(K). Myc-CaP cells were transfected with two different P-Rex1 shRNAs, and the effect on P-Rex1 expression was quantified by qPCR (right). These cells were
implanted into NSG mice, and tumor onset was determined by palpation (left).
Error bars represent mean ± SD. Bev, bevacizumab; hIgG, control immunoglobulin G. See also Figures S5–S7.
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